论文部分内容阅读
最初新辅助化疗的应用目的是为了提高本已失去手术时机的局部晚期乳腺癌手术切除率,后逐渐应用于可手术患者的保乳手术,目前已成为乳腺癌系统治疗的常规方案。病理完全缓解率是评价新辅助化疗疗效的重要指标之一。与病理完全缓解率密切相关的生物因子的识别及检测将有助于了解个体对化疗的反应,从而利于个体化的治疗。已有研究表明,一些生物因子如雌激素受体、孕激素受体、c-erbB2等与化疗疗效有密切关系,目前结论不一,各因子对疗效的预测价值不一致,而这些因子自身表达可能受化疗的影响。
The initial application of neoadjuvant chemotherapy is to improve the chance of locally advanced breast cancer surgery has lost the chance of surgery, and gradually applied to the operation of breast-conserving surgery in patients with breast cancer has now become the general program of treatment. Pathological complete remission rate is to evaluate the efficacy of neoadjuvant chemotherapy one of the important indicators. The identification and detection of biological factors that are closely related to the rate of complete remission of the pathology will help to understand the individual’s response to chemotherapy and thus facilitate individualized treatment. Some studies have shown that some biological factors such as estrogen receptor, progesterone receptor, c-erbB2, etc. are closely related to the efficacy of chemotherapy, the current conclusions are different, the predictive value of each factor on the efficacy of inconsistency, and these factors may express their own Affected by chemotherapy.